Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. (Q40896395)

24 September 2017

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. (English)

1 reference

24 September 2017

O'Hagan DT

1

1 reference

24 September 2017

Ugozzoli M

2

1 reference

24 September 2017

Barackman J

3

1 reference

24 September 2017

Singh M

4

1 reference

24 September 2017

Kazzaz J

5

1 reference

24 September 2017

Higgins K

6

1 reference

24 September 2017

Vancott TC

7

1 reference

24 September 2017

Ott G

8

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

24 September 2017

1 reference

24 September 2017

18

1 reference

24 September 2017

17

1 reference

24 September 2017

1793-1801

1 reference

Human studies in the development of human immunodeficiency virus vaccines

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Induction of HIV‐1 envelope (gp120)‐specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell‐derived gp120 is enhanced by enzymatic removal of N‐linked glycans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900522-8

7 January 2021

10.1016/S0264-410X(99)00522-8

Identifiers

DOI

1 reference

24 September 2017

1 reference